Alcoa R&D decreased by 9.1% to $10.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 16.7%, from $12.00M to $10.00M. Over 3 years (FY 2021 to FY 2024), R&D shows an upward trend with a 22.5% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.00M | $8.00M | $10.00M | $9.00M | $7.00M | $7.00M | $9.00M | $10.00M | $6.00M | $9.00M | $14.00M | $11.00M | $13.00M | $16.00M | $17.00M | $12.00M | $12.00M | $11.00M | $10.00M |
| QoQ Change | — | +33.3% | +25.0% | -10.0% | -22.2% | +0.0% | +28.6% | +11.1% | -40.0% | +50.0% | +55.6% | -21.4% | +18.2% | +23.1% | +6.3% | -29.4% | +0.0% | -8.3% | -9.1% |
| YoY Change | — | — | — | — | +16.7% | -12.5% | -10.0% | +11.1% | -14.3% | +28.6% | +55.6% | +10.0% | +116.7% | +77.8% | +21.4% | +9.1% | -7.7% | -31.3% | -16.7% |